Thermo Fisher Scientific Inc.
TMO
$496.11
-0.87%
Thermo Fisher Scientific, Inc. is a global leader in the healthcare sector, specifically within the Medical - Diagnostics & Research industry, providing essential scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents. The company is a dominant market leader and consolidator, distinguished by its comprehensive, integrated portfolio across four key segments: analytical technologies, specialty diagnostic products, life science solutions, and lab products and services, which includes contract research organization (CRO) capabilities. The current investor narrative revolves around navigating a post-pandemic normalization of demand, with attention focused on the company's ability to drive organic growth beyond its COVID-19-related windfall, execute on its capital deployment strategy for acquisitions, and expand margins through operational efficiency in a potentially softer macroeconomic environment for life sciences tools.…
TMO
Thermo Fisher Scientific Inc.
$496.11
Investment Opinion: Should I buy TMO Today?
Rating & Thesis: Hold. TMO is a high-quality company caught in a cyclical downturn and valuation reset; investors should wait for clearer signs of fundamental stabilization or a deeper margin of safety before committing new capital. This aligns with the data showing severe price deterioration (-19.83% over 3 months) despite bullish analyst targets implying >30% upside.
Supporting Evidence: The forward P/E of 18.14x is reasonable for a market leader, but the elevated trailing P/E of 32.34x and P/S of 4.89x suggest the market is still digesting peak earnings. Revenue growth, while positive at 7.2% YoY in Q4, is decelerating sequentially. Profitability remains solid with a net margin of 16.17%, and immense TTM FCF of $6.29 billion provides a floor. The key support is analyst consensus, with an estimated EPS of $36.24 implying a ~$657 target, but technicals severely contradict this optimism.
Risks & Conditions: The two biggest risks are 1) further multiple compression if growth disappoints, and 2) a breakdown below the $464 support level extending the downtrend. This Hold would upgrade to a Buy if the forward P/E compresses to 16x (approx. $580 price on $36.24 EPS) or if quarterly revenue growth re-accelerates above 8% organically. It would downgrade to Sell on a sustained break below the 52-week low of $385.46. Currently, the stock appears fairly valued to slightly overvalued relative to its near-term growth trajectory, but undervalued on a longer-term, normalized earnings basis.
Sign up to view all
TMO 12-Month Price Forecast
The outlook is one of conflicted signals: strong fundamentals versus weak price action. The base case of a gradual recovery is most probable, as the company's cash generation and market position provide resilience, but the sector headwinds are real. The forward valuation already prices in a growth slowdown, limiting near-term downside unless a recession hits. The stance would upgrade to Bullish on a confirmed technical reversal above $550 on strong volume, coupled with evidence of sequential revenue re-acceleration. It would turn Bearish on a breakdown below $464 with deteriorating sell-side sentiment.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $644.94 and implied upside of +30.0% versus the current price.
Average Target
$644.94
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$397 - $645
Analyst target range
Analyst coverage for TMO is substantial, with data indicating at least six major firms providing estimates, and recent institutional ratings show a strongly bullish consensus, with firms like Barclays, Citigroup, Morgan Stanley, and Wells Fargo maintaining 'Overweight' or 'Buy' ratings. The consensus implies significant upside, as the average estimated EPS for the forward period is $36.24, which, when applied to the forward PE of 18.14x, suggests a target price in the mid-$650s, representing substantial upside from the current price of $496.11, though a precise average target price is not provided in the data. The target range, inferred from estimated EPS highs and lows of $36.56 and $35.91, is relatively tight, indicating strong analyst conviction in the company's earnings trajectory; the high-end targets likely assume successful execution on margin expansion and strategic M&A, while the low-end targets may factor in a prolonged downturn in life sciences capital spending or integration risks. The pattern of recent ratings, including an upgrade from Citigroup to 'Buy' from 'Neutral' in December 2025, suggests a building positive sentiment that the stock's significant pullback has created an attractive entry point for a high-quality, cash-generative market leader.
Bulls vs Bears: TMO Investment Factors
The evidence presents a classic battle between deteriorating price momentum and underlying fundamental strength. The bear case, led by severe technical breakdown and growth deceleration, currently has stronger near-term evidence, as reflected in the stock's dramatic underperformance. However, the bull case is fortified by robust analyst conviction, a compelling forward valuation, and exceptional cash generation. The single most important tension is whether the current forward P/E of 18.14x accurately prices in the 'new normal' of mid-single-digit organic growth, or if further multiple compression is needed as the post-pandemic era fully settles. The resolution of this valuation debate will dictate the stock's direction.
Bullish
- Strong Analyst Conviction & Upside: Analysts maintain a strongly bullish consensus with an average forward EPS estimate of $36.24. Applying the forward P/E of 18.14x implies a target price near $657, representing over 32% upside from the current $496.11. Recent upgrades, like Citigroup's move to 'Buy', signal building positive sentiment on the pullback.
- Robust Cash Generation & Financial Health: The company generates immense free cash flow, with TTM FCF of $6.29 billion. This supports a strong balance sheet with a manageable debt-to-equity ratio of 0.76 and a healthy current ratio of 1.89. This financial fortress provides flexibility for strategic M&A, share buybacks, and dividends.
- Attractive Forward Valuation: The forward P/E of 18.14x represents a significant discount to the trailing P/E of 32.34x, reflecting market expectations for earnings normalization and growth. This forward multiple is more reasonable for a market leader and suggests the recent sell-off has priced in near-term headwinds.
- Market Leadership & Diversified Portfolio: As a global leader across diagnostics, life sciences, and lab services, TMO's integrated, diversified portfolio provides resilience. Its four-segment structure, including a CRO business, creates a comprehensive offering that is difficult for competitors to replicate, supporting long-term customer retention.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a pronounced downtrend, down 19.83% over three months and 16.27% YTD, dramatically underperforming the S&P 500 by -17.73% and -15.91% over those periods, respectively. Trading at 77% of its 52-week range indicates persistent selling pressure and broken momentum.
- Revenue Deceleration & Growth Normalization: Q4 2025 revenue grew 7.2% YoY, but sequential quarterly revenue in 2025 shows deceleration from $10.36B in Q1 to $12.22B in Q4, indicating a challenging post-COVID growth environment. This normalization pressures the premium valuation historically awarded for high growth.
- Elevated Trailing Valuation vs. Peers: Despite the pullback, TMO's trailing P/E of 32.34x and P/S of 4.89x remain elevated compared to typical healthcare equipment peers. This premium leaves the stock vulnerable to multiple compression if organic growth fails to re-accelerate, especially in a higher-rate environment.
- Margin Pressure Amid Cost Inflation: Profitability is facing headwinds, with the Q4 2025 net margin of 16.17% down slightly from 16.06% a year ago. The TTM operating margin of 18.20% reflects ongoing cost pressures, which could limit earnings growth if the company cannot fully offset inflation through pricing or efficiency.
TMO Technical Analysis
The stock is in a pronounced downtrend, having declined 19.83% over the past three months and 16.27% year-to-date as of the current date, which starkly contrasts with its positive 16.07% gain over the past year. Currently trading at $496.11, the price sits at approximately 77% of its 52-week range, calculated from a low of $385.46 to a high of $643.99; this positioning near the lower end of the range suggests the stock is approaching potential value territory but remains under significant selling pressure, indicating a 'falling knife' scenario that requires caution. Recent momentum shows a slight 7.87% gain over the past month, which may signal a tentative stabilization or short-term bounce within the broader downtrend, yet this positive one-month move is overwhelmed by the severe three-month and YTD losses, highlighting a deep and persistent bearish trend. The stock's beta of 0.972 indicates its volatility is nearly in line with the broader market (SPY), but its relative strength figures are deeply negative, with a 1-year relative strength of -13.45%, showing it has dramatically underperformed the market's 29.52% gain. Key technical levels are clear, with immediate resistance at the recent highs near the 52-week high of $643.99 and strong support at the 52-week low of $385.46; a sustained breakdown below the recent March low of $464.37 would signal a continuation of the downtrend toward the ultimate support zone, while a recovery above the $520-$550 area is needed to suggest a meaningful reversal is underway.
Beta
0.97
0.97x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$385-$644
Price range past year
Annual Return
+16.1%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | +2.6% |
| 3m | -19.8% | -2.3% |
| 6m | -5.5% | +2.6% |
| 1y | +16.1% | +27.3% |
| ytd | -16.3% | -0.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Revenue growth has decelerated from the pandemic peak but remains positive, with Q4 2025 revenue of $12.215 billion representing a 7.2% year-over-year increase; however, examining sequential quarters reveals a trend of revenue deceleration through 2025, from $10.364 billion in Q1 to the Q4 figure, indicating a challenging growth environment post-COVID tailwinds. The company is highly profitable, with Q4 2025 net income of $1.975 billion and a net margin of 16.17%, supported by a solid gross margin of 37.95%; profitability metrics have shown some pressure, as the Q4 net margin of 16.17% is down from 16.06% in the year-ago quarter, and the trailing twelve-month operating margin stands at 18.20%, reflecting ongoing but managed cost pressures. The balance sheet and cash flow position remain robust, with a debt-to-equity ratio of 0.76 indicating moderate leverage, a strong current ratio of 1.89 ensuring ample liquidity, and the company generated substantial free cash flow of $6.293 billion over the trailing twelve months; this powerful cash generation, evidenced by a free cash flow margin derived from the TTM FCF and recent revenue, provides significant financial flexibility for strategic acquisitions, share repurchases, and dividends, underpinning the company's financial health.
Quarterly Revenue
$12.2B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.37%
Latest Quarter
Free Cash Flow
$6.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given the company's substantial positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 32.34x and a forward PE of 18.14x based on estimated EPS; the significant gap between trailing and forward multiples reflects market expectations for a sharp recovery in earnings growth, as the forward PE implies a more normalized earnings profile. Compared to sector averages, TMO's trailing PE of 32.34x and Price-to-Sales (PS) ratio of 4.89x are elevated relative to typical healthcare equipment and supplies peers, which often trade at lower multiples; this premium is historically justified by the company's market-leading position, resilient cash flows, and growth-through-acquisition strategy, but the current premium may be contracting as growth normalizes. Historically, the current trailing PE of 32.34x is below the stock's own multi-year highs seen above 40x in early 2023 and 2024 but above the lows near 20x during peak earnings periods in 2021-2022; this positioning in the mid-to-upper range of its historical band suggests the market is still pricing in a relatively optimistic long-term outlook, though not at peak exuberance, leaving room for multiple compression if growth disappoints.
PE
32.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is not solvency—the balance sheet is strong—but rather earnings volatility and margin pressure as growth normalizes. The Q4 net margin of 16.17% shows slight YoY contraction, and the high trailing P/E of 32.34x creates vulnerability if earnings disappoint. Revenue concentration is mitigated by a diversified portfolio, but the entire business is exposed to a potential prolonged downturn in life sciences capital spending, which could pressure the high-margin Analytical Technologies and Life Science Solutions segments, comprising 40% of sales.
Market & Competitive Risks: The stock faces significant valuation compression risk, trading at a premium P/E and P/S versus sector peers. Its beta of 0.972 indicates market-correlated moves, meaning a broader sell-off in growth or healthcare stocks would likely drag TMO lower. Competitive risks are moderate given its scale and integration, but innovation from smaller, nimble firms in high-growth niches like gene therapy tools could erode long-term market share. The lack of a meaningful dividend (yield 0.29%) offers little downside cushion for income-focused investors during sector rotations.
Worst-Case Scenario: The worst-case involves a deepening recession in biopharma R&D spending, causing organic revenue growth to turn negative, coupled with a failed acquisition that dilutes earnings. This could trigger multiple compression towards the stock's historical low P/E near 20x on depressed earnings. The realistic downside would see the stock re-test its 52-week low of $385.46, representing a loss of approximately -22% from the current price of $496.11. A breach of that level could trigger further technical selling towards the $350s, amplifying losses for investors buying at current levels.
FAQ
The key risks are: 1) Growth/Multiple Compression Risk: If organic growth decelerates further, the still-elevated trailing P/E of 32x could compress sharply. 2) Sector Cyclicality: The stock is highly correlated (beta 0.97) to the market and sensitive to biopharma R&D spending cuts. 3) Execution Risk: Future growth relies partly on successful M&A; overpaying or poor integration could destroy value. 4) Technical Risk: The stock is in a severe downtrend; a break below $464 support could trigger further algorithmic selling. The growth/multiple risk is currently the most severe.
Our 12-month forecast outlines three scenarios. The Base Case (60% probability) sees the stock trading between $550 and $600 as growth stabilizes and it trades on its forward P/E. The Bull Case (25% probability) targets $657 to $700 on a sector rebound and multiple expansion. The Bear Case (15% probability) warns of a retest of the 52-week low between $385 and $480 if growth disappoints. The Base Case is most likely, anchored by analyst EPS estimates of $36.24 and the assumption that current headwinds are cyclical, not secular.
TMO's valuation is in transition. Based on trailing earnings (P/E of 32.34x) and sales (P/S of 4.89x), it appears overvalued compared to sector peers, reflecting peak pandemic earnings. However, the forward P/E of 18.14x, based on estimated EPS of $36.24, suggests the market is pricing in a more normalized, mid-single-digit growth profile, which could be fair or slightly undervalued for a company of its quality. The valuation implies the market expects successful navigation of post-pandemic normalization without a severe downturn.
TMO presents a complex risk/reward. For long-term investors, the current forward P/E of 18.14x and over 30% implied upside to analyst targets are attractive for a market leader. However, the severe technical downtrend and revenue deceleration create near-term risk. It is a good buy for patient, valuation-sensitive investors willing to average in over time, but not for short-term traders or those sensitive to volatility. The biggest downside risk is a further slide to the 52-week low of $385.46 (-22%), while the upside is a return to the $650s.
TMO is unequivocally suitable for long-term investment, with a recommended minimum holding period of 3-5 years. Its low dividend yield (0.29%) and current high volatility make it a poor income or short-term trading vehicle. The company's value proposition is its durable market leadership and compounding cash flows over time. Long-term investors can benefit from its capital allocation strategy and industry consolidation, while weathering the cyclical downturns that make short-term performance so unpredictable.